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Contemporary Results of Surgical Resection of Non-small
Cell Lung Cancer After Induction Therapy
A Review of 549 Consecutive Cases
Stephen A. Barnett, MBBS,* Valerie W. Rusch, MD,* Junting Zheng, MS,† Bernard J. Park, MD,*
Nabil P. Rizk, MD,* Gabriel Plourde, BS,* Manjit S. Bains, MD,* Robert J. Downey, MD,*
Ronglai Shen, PhD,† and Mark G. Kris, MD‡
Objective: We previously reported a high mortality after induction
therapy and pneumonectomy for non-small cell lung cancer. Recent
reports suggest that operative mortality in these patients is declining.
We analyzed our contemporary results to define operative mortality
and factors determining surgical risk.
Methods: Eligible patients were identified from our prospective
surgical database. Complications were graded according to the
National Cancer Institute Common Terminology Criteria for Ad-
verse Events 3.0. Uni- and multivariate logistic regression models
assessed the association of preoperative tests and clinical character-
istics with outcome. Receiver operating characteristic curves and
area under the receiver operating characteristic curve (AUC) statis-
tics were calculated in a leave-one-out crossvalidation scheme to
evaluate the predictive value of various models.
Results: From January 2000 to December 2006, 549 patients un-
derwent surgery after induction therapy. Median patient age was 64
years (range: 30–86), and 54% were women (298/549). All received
chemotherapy, and 17% also had radiation. Lobectomy (388/549,
71%) and pneumonectomy (70/549, 13%) were the most common
procedures. Complications occurred in 250 patients (46%), with
grade 3 or higher in 23% (126/549). Inhospital mortality was 1.8%
(10/549), with only one death after right pneumonectomy (1/30,
3%). Multivariate analysis showed that predicted postoperative
(PPO) pulmonary function was associated with postoperative mor-
bidity. By receiver operating characteristic curves, PPO product
(AUC  0.75, p  0.001), PPO diffusion capacity (AUC  0.70,
p  0.001), and preoperative % predicted PPO diffusion capacity
(AUC  0.66, p  0.001) predicted mortality.
Conclusion: Our current experience shows that resection of non-
small cell lung cancer after induction therapy, including pneumo-
nectomy, is associated with low mortality. PPO pulmonary function
is the strongest predictor of operative risk and should be used to
select patients for surgery.
Key Words: Lung cancer, Neoadjuvant therapy, Induction therapy,
Surgical morbidity and mortality.
(J Thorac Oncol. 2011;6: 1530–1536)
Despite recent advances in the treatment of non-small celllung cancer (NSCLC), long-term survival, even in early
stage disease, is poor.1,2 Nevertheless, in locally advanced
disease, the addition of chemotherapy to surgical resection
has been shown to improve survival rates relative to surgery
alone.3–10 Although induction chemotherapy is well toler-
ated,9,10 prior studies, including a large one from our institu-
tion, reported high rates of postoperative morbidity and
mortality in patients with NSCLC who received induction
treatment.11–13 We previously found that operative risk was
especially high after right pneumonectomy, which was asso-
ciated with a mortality of 23.9%. More recent series report
declining morbidity and mortality.14 In this study, we review
our contemporary experience to define the frequency and
types of postoperative adverse events after induction therapy
and to identify factors that predict these events.
METHODS
Acquisition of Clinical Data
After approval by the institutional review board, we
reviewed our prospectively maintained lung cancer database
to identify patients who underwent surgery for NSCLC after
induction therapy. Patients with superior sulcus and bilateral
synchronous tumors were excluded because these were con-
sidered subgroups with factors that might confound analyses.
Additional review of the medical record was done as needed
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to confirm patient demographics, preoperative treatment data,
and perioperative measures.
Pulmonary comorbidity was defined as any underlying
lung disease (most frequently chronic obstructive pulmonary
disease). Postoperative % predicted DLCO (PPODLCO) and
forced expiratory volume in 1 second (FEV1; PPOFEV1)
were calculated either by segmental method (preoperative
value multiplied by the number of bronchopulmonary seg-
ments remaining postoperatively and divided by 18) or by
perfusion method (preoperative value multiplied by percent-
age perfusion in the remaining lung) in cases where quanti-
tative ventilation perfusion scan was performed. PPODLCO
and PPOFEV1 were then multiplied by one another to derive
the predicted postoperative product (PPOP).15
Postoperative mortality was defined as death within 30
days of surgery or as death during the initial hospital stay if
the patient was not discharged within 30 days. Complications
were graded according to the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events version 3.0
(CTCAE 3.0) (http://ctep.cancer.gov/protocoldevelopment/
electronic_applications/docs/ctcaev3.pdf). Clinical and path-
ological tumor stages were assigned according to the 6th
edition of the International System for Staging Lung Can-
cer.16 Both CTCAE 3.0 and the 6th edition of the staging
system were in force when this study was initiated. The
extent of resection was classified as R0 (pathologically com-
plete), R1 (residual microscopic disease), and R2 (residual
macroscopic disease).
Statistical Methods
The association of PPO pulmonary function and clini-
cal characteristics with perioperative outcomes was assessed
by uni- and multivariate logistic regression. Known risk
factors such as age, gender, smoking history, comorbidities,
and surgical procedure were adjusted in the multivariate
model. Based on the univariate empirical receiver operating
characteristic (ROC) curve, the cutoff point for each mea-
surement was chosen by the Youden index.17 The ROC
curves and the area under the ROC curve (AUC) were
generated within a leave-one-out crossvalidation scheme. The
estimated risks of mortality by three measurements were
presented in smoothed curves using a secondary regression.
All statistical analyses were performed in SAS 9.2 software
(SAS Institute Inc., Cary, NC).
RESULTS
From January 2000 to December 2006, 629 consecutive
patients underwent surgical exploration after induction ther-
apy. Eighty patients were excluded (69 superior sulcus tu-
mors and 11 cases of synchronous bilateral disease) leaving
549 for analysis. Patient characteristics are listed in Table 1.
Median patient age was 64 years (range: 30–86 years), and
54% (298/549) were women. Most patients (90%) were
current or former smokers. The majority of patients under-
going preoperative therapy had clinical stage II to stage IIIA
tumors (389/549, 71%). A small number of patients (n  15)
with clinical stage IA disease were treated with preoperative
chemotherapy for various reasons (e.g., small cell lung cancer
harboring persistent NSCLC after definitive nonsurgical ther-
apy). Mean % predicted FEV1 was 85%  18% (range:
27–141), and the mean % predicted DLCO was 73%  20%
(range: 12–135).
Preoperative chemotherapy, usually cisplatin based,
was administered to 545 patients (99%), and 95 (17%) of
patients also had external beam radiotherapy. The median
radiation dose was 50 Gy (range: 15–70 Gy) and was admin-
istered concurrently to 80 of 95 (92%) and sequentially to 7
of 95 (8%) patients. Details of timing of administration in the
remaining eight patients were not available.
The details of surgery are listed in Table 2. Lobectomy
was the most common procedure. Pneumonectomy was per-
formed in 13% (70/549) of patients and was right sided in 30
of 70 patients (44%). Concomitant en bloc chest wall resec-
tion was performed in 30 patients. Complete macroscopic
resection (R0 and R1) was achieved in 89% (489/549) of
patients with RO resection in 83.4% (458/549) patients.
Perioperative Adverse Events
The median length of hospital stay was 6 days (range:
1–108). The total operative morbidity rate for the group was
TABLE 1. Patient Characteristics
Characteristics
Patients
(n  549)
Age, yr (range) 64 (30–86)
Gender (female) 298 (54%)
Smoking status
Never 56 (10.2%)
Former 424 (77%)
Current 69 (13%)
Mean pack years (SD) 43 (32)
Comorbidities
Pulmonary 133 (24%)
Cardiac 222 (40%)
Renal 7 (1%)
Endocrine 40 (7%)
Other 127 (23%)
Pretreatment clinical stage
IA 15 (3%)
IB 68 (12%)
IIA 8 (1%)
IIB 83 (15%)
IIIA 305 (56%)
IIIB 49 (9%)
IV 21 (4%)
Pulmonary function mean (SD)
FEV1 % predicted 85 (18)
DLCO % predicted 73 (20)
PPOFEV1 segmental 66 (18)
PPODLCO segmental 57 (19)
PPOP segmental 40 (21)
PPOFEV1 perfusion 63 (16)a
PPODLCO perfusion 55 (16)a
a Quantitative perfusion scans were undertaken in 193/549 patients (35%).
PPO, predicted postoperative; FEV1, forced expiratory volume in 1 second; DLCO,
PPO diffusion capacity; PPOP, predicted postoperative product.
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46% (250/549). The majority of complications were pulmo-
nary (Table 3). Grade 3 or greater adverse events occurred in
23% of patients (126/549), but grades 4 and 5 complications
occurred in only 4.5% (15/549) of patients. Perioperative
mortality rate was 1.8% (10/549) with pulmonary complica-
tions accounting for 100% (10/10) of deaths. Table 2 lists the
morbidity and mortality rates in relationship to the extent of
pulmonary resection. There were no substantial differences,
except that exploration only had the lowest morbidity. Of
note, the overall mortality rate for pneumonectomy was 4.3%
(5% for left and 3.3% for right-sided resections).
Predictors of Postoperative Adverse Events by
Univariate Analyses
By univariate analysis, increasing age (odds ratio [OR]
1.287 [1.089–1.521], p 0.003 for each 10-year increment in
age), pulmonary comorbidity (OR  1.964 [1.319–2.925],
p  0.001), and chest wall resection (OR  4.614 [1.855–
11.47], p  0.001) were associated with an increased risk of
adverse events. The values inside the square parenthesis
marks are the 95% confidence interval of the OR. Gender,
smoking history, induction regimen, and extent of lung re-
section did not affect outcome. Underlying pulmonary co-
morbidity was also significantly associated with pulmonary
complications (OR 1.873 [1.226–2.860], p 0.004), grade
4 or 5 adverse events (OR  3.647 [1.621–8.204], p 
0.002), and mortality (OR  4.866 [1.352–17.51], p 
0.015). Chest wall resection similarly was associated with
higher risk of pulmonary complication (OR  3.119 [1.483–
6.559], p  0.003) and severe complications (OR  4.990
[1.730–14.39], p  0.003).
Decreased values of almost every measure of pulmonary
function were associated with increased pulmonary complica-
tion rate (data not shown), except PPOFEV1perf (OR  0.836
[0.684–1.021], p  0.08). Reductions in DLCO (OR  1.451
[1.000–2.105], p 0.05), PPODLCOseg (OR 1.905 [1.205–
3.012], p 0.006), PPOFEV1seg (OR 1.715 [1.149–2.564],
p  0.008), PPODLCOperf, (OR  2.000 [1.040–3.846], p 
0.038), and PPOPseg (OR  2.242 [1.248–4.016], p  0.007)
were each associated with increased mortality.
Predictors of Postoperative Adverse Events by
Multivariate Analysis
By multivariate analysis adjusted for age, gender,
smoking status, type of procedure, use of preoperative radi-
ation, use of cisplatin, and comorbidities, decreasing mea-
sures of preoperative pulmonary function were associated
with increased risk of pulmonary complications and grades 4
and 5 adverse events (Table 4). Nevertheless, none of these
factors was statistically significant with respect to mortality.
ROC curves revealed PPOPseg along with PPOFEV1seg to
be the best predictors of severe complications (Table 5).
PPOPseg (AUC  0.75, p  0.001), PPODLCOseg (AUC 
TABLE 2. Operative Details
Procedure
No. of Patients,
N (%)
Morbidity,
N (%)
Mortality,
N (%)
Pneumonectomy 70 (13) 38 (54) 3 (4.3%)
Right 30 (6) 18 (60) 1 (3.3%)
Left 40 (7) 20 (50) 2 (5.0%)
Bilobectomy 32 (6) 17 (53) 2 (6.3%)
Lobectomy 356 (65) 169 (47) 4 (1.1%)
Segmentectomy 12 (2) 6 (50) 0
Wedge 29 (5) 13 (45) 0
Exploration 50 (9) 14 (28) 1 (2.0%)
Histology N (Total  545)
Squamous 106
Adenocarcinoma 328
BAC 5
Large cell undiff 0
NSC NOS 91
Large cell neuroendocrine 11
Carcinoid 4
NOS, not otherwise specified; NSC, non small cell; BAC, bronchioloalveolar
carcinoma.
TABLE 3. Adverse Events in 250 Patients
Complication
Grades
1 2 3 4 5
Pulmonary (n  192, 43%)
Pneumonitis (50) 2 12 20 9 7
Hypoxia (38) 18 20
Prolonged air leak (36) 2 31 3
Pneumothorax (20) 1 16 3
Atelectasis (29) 28 1
Pleural effusion (9) 3 5 1
Empyema (4) 1 2 1
Hemoptysis 2
Prolonged intubation 1
Cardiac (n  79, 18%)
Supraventricular tachycardia (73) 3 67 3
Myocardial infarction (2) 2
Other (4) 2 2
Hematologic (n  64, 14%)
Hemorrhage (40) 2 1 36 1
Deep venous thrombosis (12) 5 7
Pulmonary embolism (12) 7 3 1 1
Infectious (n  49, 11%)
Urinary tract infection (15) 2 5 8
Wound infection (6) 4 1 1
Other (28) 1 4 23
Neurologic (n  33, 7%)
Vocal cord paralysis (19) 5 5 9
TIA/CVA (2) 1 1
Other (12) 1 7 4
Urologic (n  9, 2%)
Renal failure (7) 1 2 4
Urinary retention (2) 1 1
Chylothorax (n  7, 1.5%) 1 2 3 1
Other (n  5, 1%) 2 2 1
The total number of complications (n  446) exceeds the number of patients
because some patients had multiple adverse events.
TIA, transient ischemic attack; CVA, cerebrovascular accident.
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0.71, p  0.001), and baseline DLCO (AUC  0.66, p 
0.001) were the best predictors of postoperative mortality.
When PPOPseg, PPODLCOseg, and baseline DLCO were
analyzed in relationship to operative mortality (Table 6),
cutpoints were identified and found to be associated with a
transition in risk after which rates of mortality begin to rise
significantly (Figure 1).
DISCUSSION
This study, one of the two largest contemporary series
analyzing surgical outcomes in patients with NSCLC after
induction therapy,14 shows that operative mortality is low and
that thorough assessment of preoperative pulmonary function
is critical in patient selection. This experience is a unique
addition to the published literature because the data were
collected prospectively, adverse events recorded uniformly
according to CTCAE criteria, and extensive preoperative
pulmonary function data were available. The perioperative
mortality rate of 1.8% is even lower than reported in our
earlier experience (3.8%)12 and is at the lower end of mor-
tality reported for resection after induction therapy and even
after surgery alone in both retrospective series and prospec-
tive clinical trials.18–35 Potential explanations for these excel-
lent results include careful patient selection, longstanding
institutional expertise in multimodality therapy, and a high
frequency of lobectomy relative to pneumonectomy (13%
versus 26% in our earlier series).
Earlier retrospective series11,12,14,21,25,29–35 and prospec-
tive clinical trials13 report a high mortality for patients un-
dergoing pneumonectomy after induction therapy, especially
right pneumonectomy. In this study, the operative mortality
after pneumonectomy was only 4.3%, a sharp decline from
our previous experience (11.3%).12 This was particularly
FIGURE 1. Risk of operative mortality in relationship to
baseline PPO diffusion capacity (DLCO), postoperative %
predicted DLCO (PPODLCO) (seg), and predicted postopera-
tive product (PPOP) (seg).
TABLE 4. Multivariable Analysis for Complication Outcomes
Measurement
of Pulmonary
Functionb N
Overall Complications Pulmonary Complications Severe Complications Mortality
OR (95% CI)a p OR (95% CI)a p OR (95% CI)a p OR (95% CI)a p
FEV1 502 0.769 (0.681–0.867) .001 0.789 (0.688–0.905) .001 0.652 (0.486–0.874) 0.004 0.814 (0.491–1.349) 0.424
PPOFEV1 (seg) 502 0.746 (0.648–0.858) .001 0.800 (0.682–0.938) 0.006 0.553 (0.381–0.804) 0.002 0.634 (0.313–1.285) 0.206
PPOFEV1 (perf) 182 0.784 (0.635–0.969) 0.024 0.867 (0.693–1.084) 0.211 0.629 (0.406–0.975) 0.038 0.660 (0.307–1.416) 0.286
DLCO 495 0.862 (0.776–0.958) 0.006 0.771 (0.679–0.875) .001 0.849 (0.658–1.095) 0.207 0.731 (0.442–1.209 0.222
PPDDLCO (seg) 495 0.840 (0.739–0.954) 0.007 0.769 (0.660–0.896) .001 0.731 (0.519–1.030) 0.074 0.511 (0.233–1.123) 0.095
PPODLCO (perf) 181 0.830 (0.676–1.019) 0.075 0.778 (0.620–0.977) 0.031 0.688 (0.455–1.042) 0.077 0.233 (0.033–1.631) 0.142
PPOP (seg) 495 0.804 (0.710–0.911) .001 0.774 (0.665–0.899) .001 0.528 (0.339–0.824) 0.005 0.321 (0.095–1.089) 0.068
PPOP (perf) 181 0.778 (0.636–0.952) 0.015 0.783 (0.625–0.982) 0.034 0.507 (0.292–0.879) 0.016 0.146 (0.015–1.434) 0.099
a OR corresponds to 10-point increasing.
b Each measurement fitted and adjusted for age, gender, smoking status, procedures, radiotherapy, cisplatin use, and comorbidities.
OR, odds ratio; CI, confidence interval; FEV1, forced expiratory volume in 1 second; PPOP, predicted postoperative product; PPO, predicted postoperative; DLCO, PPO diffusion
capacity.
TABLE 5. AUC Statistics of Predictors for Severe Complications
Measure of Pulmonary
Function AUC 95% CI
FEV1 0.685 0.590–0.780
PPOFEV1 (seg) 0.704 0.612–0.797
PPOFEV1 (perf) 0.588 0.437–0.738
DLCO 0.593 0.464–0.723
PPODLCO (seg) 0.620 0.491–0.748
PPODLCO (perf) 0.527 0.367–0.687
PPOP (seg) 0.693 0.579–0.808
PPOP (perf) 0.617 0.482–0.753
CI, confidence interval; AUC, area under the receiver operating characteristic
curve; FEV1, forced expiratory volume in 1 second; PPOP, predicted postoperative
product; PPO, predicted postoperative; DLCO, PPO diffusion capacity.
TABLE 6. Cutoff Points for Evaluation of the Risk of Mortality
Cutoff
Point Sensitivity Specificity
ROC
Area
(AUC)
AUC
95% CI
Baseline
DLCO
58% 0.86 0.56 0.663 0.440–0.885
PPODLCO
(seg)
43% 0.71 0.71 0.701 0.503–0.899
PPOP (seg) 22% 0.86 0.65 0.754 0.610–0.898
AUC, area under the ROC curve; CI, confidence interval; ROC, receiver operating
characteristic; PPOP, predicted postoperative product; PPO, predicted postoperative;
DLCO, PPO diffusion capacity.
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evident among patients undergoing right pneumonectomy
where we observed only one death (3%) compared with a
previous mortality rate of 24%. This confirms more recent
experience from other institutions (Table 7).
The decline in postpneumonectomy mortality is likely
multifactorial in nature. Analysis of our earlier experience
showing a high postpneumonectomy mortality prompted
more careful patient selection and greater attention to pulmo-
nary function evaluation. We performed fewer pneumonec-
tomies in the current series than in our previous experience
(13% versus 20.6%), including fewer right pneumonectomies
(30/70, 43% versus 46/97, 47%). The reasons for this are not
clear but could be related to more careful patient selection, to
a shift in tumor types from squamous cell to adenocarcinoma,
and to a shift in location from central to peripheral lesions.
Greater attention to pulmonary function evaluation is sug-
gested by the fact that quantitative perfusion scans were
obtained in 35% (193/549) of patients compared with 13%
(63/470) in our previous experience. In addition, there has
been an evolution in the types of induction therapy agents
used at our institution, away from those associated with
pulmonary toxicity (e.g., mitomycin).
Our overall complication rate was 48% and at first
glance appears excessive when compared with previous ret-
rospective, phase II and randomized studies of induction
therapy followed by surgery (morbidity rates of 10–
38%).11,19–23 This is likely explained by our strategy of
prospectively capturing complications in our database and
recording all adverse events using CTCAE criteria.
Since the 1970s, preoperative FEV1 has traditionally
been relied on to predict risk of adverse outcome after lung
resection.36 Nevertheless, more recent studies suggest that
DLCO is an independent predictor of both pulmonary com-
plications37 and operative mortality.38–40 We found DLCO
(both baseline and PPO DLCO) to be the parameter most
closely associated with overall complication rate, pulmonary
complications, grade 3 or higher adverse events and mortal-
ity. This single measure, using a cutpoint of 58% predicted,
identified patients who subsequently died as a result of
surgery with a sensitivity of 86% and specificity of 56%. The
risk of perioperative mortality began to accelerate at values
less than 55%. Using a cutpoint of 58% predicted, the
negative predictive value of baseline DLCO was 99.5%;
however, the positive predictive value (likely due to our low
overall mortality) was only 5.5%. This implies that patients
with preserved DLCO may be operated on safely but that
although mortality may rise as DLCO falls, a value less
than 58% may not necessarily preclude a satisfactory
postoperative outcome. Therefore, we recommend that
DLCO be measured in all patients before resection and that
PPO DLCOseg be calculated in patients with diminished
preoperative pulmonary function.
Compared with other measures, PPODLCOseg has
been proposed as the best predictor of outcome.41,42 Scoring
systems using a combination of measured and predicted lung
function with other prognostic factors have been used to
further improve risk stratification, but even “simple” ones are
not easy to calculate in an office setting.43 The value of the
PPOPseg in quantifying perioperative risk in patients before
lung resection was first elucidated by Pierce et al.15 and
remains a simple method for stratifying patients. In this study,
the PPOPseg was found on ROC curve analysis to be the best
predictor of post operative mortality, identifying patients who
died postoperatively with a sensitivity of 86% and specificity
of 65%. The risk of perioperative death increased dramati-
cally at values less than 22%. In conjunction with DLCO,
PPODLCOseg, PPOPseg provides a reliable assessment of
surgical risk and can be used to refine patient selection.
The major limitation of this study is the retrospective
nature of this review. Although the potential inaccuracy of
retrospective data collection was mitigated by the meticulous
maintenance of our prospective database and supplemental
chart review, there is unavoidable selection bias in the patient
population. It is unknown how many potential patients were
screened by clinicians and considered ineligible for induction
therapy or surgery and on what grounds such decisions were
made. Further, there is no information available on patients
who refused treatment or never made it to surgical resection
for other medical reasons.
TABLE 7. Reports of Pneumonectomies After Induction Therapy for NSCLC
First Author
Chemotherapy
Only
Chemo and
Radiotherapy
No. of
Pneumonectomies
% Operative
Deaths
Roberts et al.31 Y 20 0
Martin et al.12 Y 97 24
Stamatis et al.32 Y 127 7.2
Matsubara et al.33 Y 68 4
Sonnet et al.21 Y 11 0
Doddoli et al.11 Y 100 12
Van Schil et al.25 Y 69 7.2
Perrot et al.34 Y 27 3.7
Daly et al.29 Y 30 13.3
Mansour et al.35 Y 60 6.7
Gudbjartsson et al.30 Y 35 0
Weder et al.14 Y Y 176 3
NSCLC, non-small cell lung cancer; Y, yes.
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Induction chemotherapy and subsequent surgical resec-
tion, including right pneumonectomy, for NSCLC are safe in
selected patients. Pulmonary comorbidity and reserve are the
prime determinants of postoperative morbidity, particularly
severe and pulmonary complications. Baseline DLCO is an
important preoperative indicator of operative risk and
should be evaluated along with FEV1 before anatomic
resection. Diminishing PPODLCO is strongly associated
with postoperative morbidity and mortality and should
influence decisions regarding the suitability of any patient
for major pulmonary resection, particularly after induction
chemotherapy.
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